Summary
A bioRxiv preprint reports that harmine plus exendin-4, given after low-dose anti-CD3 therapy, promoted remission in diabetic mice. Human cell experiments also showed effects on beta-cell function and immune responses.
A bioRxiv preprint reports that harmine combined with exendin-4 improved diabetes outcomes in non-obese diabetic (NOD) mice when given after low-dose anti-CD3 therapy. The combination was associated with normalized blood glucose and enhanced remission; harmine plus exendin-4 alone did not reverse diabetes in the mice. The work also describes experiments in human beta cells and activated immune cells, but it is preclinical research, not a human treatment trial.
What the combination changed in mice and cells
In the NOD mouse model, the researchers gave low-dose anti-CD3 first, followed by harmine plus exendin-4. They report that blood glucose normalized, insulin levels and glucose tolerance improved, and beta-cell mass increased. The combination also enhanced diabetes remission. Anti-CD3 acts on T cells, which are involved in the autoimmune attack that destroys insulin-producing beta cells in type 1 diabetes.
The researchers report a different set of findings from experiments involving human beta cells: harmine plus exendin-4 reduced inflammation-induced cell death, suppressed cytokine-signalling and immunogenicity pathways, and improved beta-cell function. In activated human peripheral blood mononuclear cells (PBMCs)—a mixture of immune cells from blood—the authors observed similar immunomodulatory effects.
The mouse immune findings included fewer pro-inflammatory T-cell responses, more regulatory T cells and increased expression of exhaustion-related T-cell markers. The authors report these changes occurred without broad lymphocyte depletion. These observations point to effects on immune activity alongside the combination’s reported benefits for beta cells.
Why the result is still preclinical
The study’s proposed approach pairs immune modulation with support for the cells that remain after autoimmune damage. That is relevant because controlling the immune attack and preserving or restoring beta-cell function are distinct challenges in type 1 diabetes. The authors identify the long non-coding RNA SNHG6 as a mediator of the combination’s effects; they report that it protected beta cells from cytokine-related stress, cell death and changes linked to immune recognition.
The central remission finding comes from mice, while the human evidence described in the abstract comes from cell experiments. It therefore does not establish that the combination can induce remission in people. The findings are from a bioRxiv preprint. The authors disclose that several researchers are inventors on patents licensed to PaulexBio, and that some are members of the company’s scientific advisory board.